Evidence map›Paper›PMID 34514016›Full record

ArticleOpen forum infectious diseases2021

Defective Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses in an Immunocompromised Individual With Prolonged Viral Replication.

Claire L Gordon, Olivia C Smibert, Natasha E Holmes, Kyra Y L Chua, Morgan Rose, George Drewett, Fiona James, Effie Mouhtouris, Thi H O Nguyen, Wuji Zhang and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 1 country.

Claire L GordonDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Olivia C SmibertDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Natasha E HolmesDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Kyra Y L ChuaDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Morgan RoseDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
George DrewettDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Fiona JamesDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Effie MouhtourisDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Thi H O NguyenDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Wuji ZhangDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Lukasz KedzierskiDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Louise C RowntreeDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Brendon Y ChuaDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Leon CalyVictorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Mike G CattonVictorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Julian DruceVictorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Michelle SaitMicrobiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Torsten SeemannMicrobiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Norelle L SherryDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Benjamin P HowdenDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Katherine KedzierskaDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Jason C KwongDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Jason A TrubianoDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia.
Austin Hospital · AUPeter Doherty Institute · AUUniversity of Melbourne · AUAustin Health · AUThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immune responses in a patient with lymphoma and recent programmed death 1 (PD-1) inhibitor therapy with late onset of severe coronavirus disease 2019 disease and prolonged SARS-CoV-2 replication, in comparison to age-matched and immunocompromised controls. High levels of HLA-DR

Indexed as

cellular immunityCOVID-19humoral immunityimmunocompromiselymphomaSARS-CoV-2

Identifiers

PMID34514016
PMCPMC8419740
OpenAlexW3190836702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.